Aruj Dhyani
Research Subjects
Aruj Dhyani has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Alice C. Wei
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication - Amit Sehrawat
Department of Medical Oncology Hematology, All India Institute of Medical Sciences Rishikesh, Rishikesh, Uttarakhand, India
1 shared publication - Ankita Pandey
Radiation Oncology, Rohilkhand Medical College and Hospital, Bareilly, India
1 shared publication - Danny N. Khalil
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
1 shared publication - Darren Cowzer
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication - David B. Solit
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
1 shared publication
Latest Publications
- Open Access
- 14 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF11
Target Antigen Identification for Antibody–Drug Conjugate Therapy in Biliary Tract Cancer
Purpose: Data on antibody–drug conjugates (ADC) target expression prevalence, intertumoral heterogeneity, and genomic concordance, and its effect on clinical outcomes is limited in biliary tract cancers. Experimental Design: Resected primary biliary tract cancer specimens and, when available, matched metastatic samples were assembled into tissue microarrays (TMA) and tested for CLAUDIN18.2 (CLDN18.2), c-MET, Nectin-4, TROP2, and HER2 expression by immunohistochemistry (IHC). A subset underwent targeted next-generation sequencing using MSK-IMPACT (NCT01775072). Exploratory associations of target expression with clinicopathologic parameters, genomic alterations, recurrence-free survival (RFS), and overall survival (OS) were evaluated. Results: Sixty-five patients with resected biliary tract cancer and 18 paired metastatic sites were identified—43% extrahepatic cholangiocarcinoma, 40% intrahepatic cholangiocarcinoma, and 17% gallbladder cancer. All evaluated target antigens were expressed; percent positivity and H-score ≥200 were 83% and 26% for TROP2, 75% and 26% for c-MET, 66% and 35% for Nectin-4, and 46% and 7.7% for CLDN18.2, respectively. HER2 overexpression occurred in 3.1% of tumors. Overall agreement among paired primary and metastatic samples on calling either positive or negative ranged from 43% to 75%, with the highest observed for HER2 {75%; κ = 0.29 [95% confidence interval (CI), −0.32 to 0.91]} and TROP2 (71%; κ not available) and lowest for c-MET, CLDN18.2, and Nectin-4. Frequently altered genes included TP53 (36%), SMAD4 (27%), and ELF3 (21%). We observed no significant association between target antigen expression and genomics, RFS, or OS. Conclusions: Biliary tract cancer displays frequent but heterogeneous expression of multiple ADC targets. These hypothesis-generating findings suggest inherent complexity of target protein quantification, target threshold determination, and target sampling discordance. Future studies will be required to refine our understanding of the utility of ADCs in biliary tract cancer.
- 14 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF11
Open AccessTarget Antigen Identification for Antibody–Drug Conjugate Therapy in Biliary Tract Cancer
Purpose: Data on antibody–drug conjugates (ADC) target expression prevalence, intertumoral heterogeneity, and genomic concordance, and its effect on clinical outcomes is limited in biliary tract cancers. Experimental Design: Resected primary biliary tract cancer specimens and, when available, matched metastatic samples were assembled into tissue microarrays (TMA) and tested for CLAUDIN18.2 (CLDN18.2), c-MET, Nectin-4, TROP2, and HER2 expression by immunohistochemistry (IHC). A subset underwent targeted next-generation sequencing using MSK-IMPACT (NCT01775072). Exploratory associations of target expression with clinicopathologic parameters, genomic alterations, recurrence-free survival (RFS), and overall survival (OS) were evaluated. Results: Sixty-five patients with resected biliary tract cancer and 18 paired metastatic sites were identified—43% extrahepatic cholangiocarcinoma, 40% intrahepatic cholangiocarcinoma, and 17% gallbladder cancer. All evaluated target antigens were expressed; percent positivity and H-score ≥200 were 83% and 26% for TROP2, 75% and 26% for c-MET, 66% and 35% for Nectin-4, and 46% and 7.7% for CLDN18.2, respectively. HER2 overexpression occurred in 3.1% of tumors. Overall agreement among paired primary and metastatic samples on calling either positive or negative ranged from 43% to 75%, with the highest observed for HER2 {75%; κ = 0.29 [95% confidence interval (CI), −0.32 to 0.91]} and TROP2 (71%; κ not available) and lowest for c-MET, CLDN18.2, and Nectin-4. Frequently altered genes included TP53 (36%), SMAD4 (27%), and ELF3 (21%). We observed no significant association between target antigen expression and genomics, RFS, or OS. Conclusions: Biliary tract cancer displays frequent but heterogeneous expression of multiple ADC targets. These hypothesis-generating findings suggest inherent complexity of target protein quantification, target threshold determination, and target sampling discordance. Future studies will be required to refine our understanding of the utility of ADCs in biliary tract cancer.
- 19 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 50, 104005
Phase II Open-Label Randomised Controlled Trial Comparing Oxaliplatin and Cisplatin Based Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Cancers
- 19 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 50, 104005
Phase II Open-Label Randomised Controlled Trial Comparing Oxaliplatin and Cisplatin Based Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Cancers